Related Experiment Video
Updated: Aug 16, 2026

Trans-vivo Delayed Type Hypersensitivity Assay for Antigen Specific Regulation
Published on: May 2, 2013
Acquired type 2a von Willebrand's disease: response to immunoglobulin infusion
B Sampson1, D R Anderson, M Dugal
1QEII Health Sciences Centre, Halifax, N.S., Canada.
Abstract:
A 75-year-old male presented with new symptoms of a bleeding diathesis associated with a decline in the functional activity of von Willebrand factor (type 2a von Willebrand's disease). Replacement therapy was ineffective and he was subsequently treated with intravenous immunoglobulin (IvIg). IvIg not only caused symptomatic improvement but was shown to transiently restore the depleted von Willebrand factor intermediate and high molecular weight multimers. Subsequent periodic IvIg infusions have been used successfully to treat bleeding complications in this patient over the past 3 years. A secondary cause for the acquired von Willebrand's disease has not been identified.
More Related Videos
18:48In Vitro and In Vivo Assessment of T, B and Myeloid Cells Suppressive Activity and Humoral Responses from Transplant Recipients
Published on: August 12, 2017
08:30Investigating von Willebrand Factor Pathophysiology Using a Flow Chamber Model of von Willebrand Factor-platelet String Formation
Published on: August 14, 2017
Related Concept Videos
Hypersensitivity Reactions: Cytolytic Reactions
Hypersensitivity Reactions: Immune-Complex Reactions